Table 1. The associations between the expression of GLS1 and GLUD1 in prostate cancers and the clinicopathological characters.

	Total	GLS1 expression		P value	GLUD1 expression		P value
		Low	High		Low	High
Ages				0.114			0.419
<70	45	32(71.1%)	13(28.9%)		21(47.7%)	24(53.3%)
≥70	42	23(54.8%)	19(45.2%)		16(38.1%)	26(61.9%)
Gleason score				0.017*			0.021*
<5	45	30(66.7%)	15(33.3%)		21(46.7%)	24(53.3%)
5-7	23	18(78.3%)	5(21.7%)		13(56.5%)	10(43.5%)
≥8	19	7(36.8%)	12(63.2%)		3(15.8%)	16(84.2%)
PSA				0.491			0.648
<100	40	23(57.5%)	17(42.5%)		17(42.5%)	23(57.5%)
≥100	40	26(65.0%)	14(35.0%)		15(37.5%)	25(62.5%)
UIGG stage				0.886			0.637
I-II	66	44(63.6%)	24(34.4%)		29(43.9%)	37(56.1%)
III-IV	21	13(61.9%)	8(38.1%)		8(38.1%)	13(61.9%)

^*P < 0.05, **P < 0.01, ***P<0.001